NovoCure (NVCR) Capital Expenditures Growth (1y) (2015 - 2026)
NovoCure (NVCR) Capital Expenditures Growth (1y) (2015 - 2026) Analysis & Trends
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.63 Bn | 194.02 Bn | 7.27 Bn | -1.00% |
| 2 | Stryker | 127.42 Bn | 123.95 Bn | 4.50 Bn | 10.38% |
| 3 | Medtronic | 118.97 Bn | 109.75 Bn | 6.41 Bn | 6.32% |
| 4 | Boston Scientific | 73.39 Bn | 72.85 Bn | 3.85 Bn | 24.20% |
| 5 | Edwards Lifesciences | 51.97 Bn | 47.72 Bn | 1.35 Bn | 35.70% |
| 6 | Dexcom | 34.32 Bn | 32.37 Bn | 830.00 Mn | -9.99% |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 16.28% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | -4.32% |
| 9 | Steris | 23.04 Bn | 22.56 Bn | 684.20 Mn | -6.52% |
| 10 | NovoCure | 2.05 Bn | 1.61 Bn | 142.48 Mn | 26.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.07% |
| Mar 31, 2026 | -51.45% |
| Dec 31, 2025 | -45.25% |
| Sep 30, 2025 | -47.07% |
| Jun 30, 2025 | -52.07% |
| Mar 31, 2025 | -9.95% |
| Dec 31, 2024 | 31.10% |
| Sep 30, 2024 | 47.29% |
| Jun 30, 2024 | 65.14% |
| Mar 31, 2024 | 93.56% |
| Dec 31, 2023 | 6.06% |
| Sep 30, 2023 | 27.18% |
| Jun 30, 2023 | 67.78% |
| Mar 31, 2023 | 19.54% |
| Dec 31, 2022 | -54.95% |
| Sep 30, 2022 | 72.98% |
| Jun 30, 2022 | 57.79% |
| Mar 31, 2022 | 27.93% |
| Dec 31, 2021 | 147.86% |
| Sep 30, 2021 | -36.27% |